Compare DexCom, Inc. (DXCM) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while NEOS S&P 500 High Income ETF trades at $53.69. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | SPYI | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $89.53 | $54.07 |
52-Week Low | $54.84 | $47.98 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
SPYI trades at $53.66, up 0.19% today, with a bullish technical signal from moving averages. The ETF has surpassed $10 billion in assets under management as of June 2026, driven by strong inflows. Recent dividends include $0.52-$0.54 per share, supporting its high-income appeal. The fund's covered-call strategy aims to deliver monthly distributions while retaining partial upside.
Outlook remains positive due to robust investor demand for income solutions, though risks include potential return of capital and fee impact. The ETF's 12% yield attracts retirees, but tax implications and market volatility require careful consideration. Competition with JEPI highlights the need for strategy differentiation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
